Argenx and zai lab announce approval of vyvgart® (efgartigimod alfa injection) for generalized myasthenia gravis in china

Amsterdam, the netherlands— june 30, 2023 -- argenx se (euronext & nasdaq: argx) and zai lab limited (nasdaq: zlab; hkex: 9688) today announced that china's national medical products administration (nmpa) has approved the biologics license application (bla) for vyvgart® (efgartigimod alfa injection), a first-in-class neonatal fc receptor (fcrn) antagonist, as an add on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gmg) who are anti-acetylcholine receptor (achr) antibody positive. zai lab will now work with the national healthcare security administration (nhsa) for nrdl inclusion to enable broad access for patients.
ARGX Ratings Summary
ARGX Quant Ranking